Abbvie partners with Genmab in $750 mln cancer therapy deal

Abbvie partners with Genmab in $750 mln cancer therapy deal
Representative Image Image Credit: Wikimedia
  • Country:
  • United States

Abbvie Inc said on Wednesday it has entered into an agreement with Genmab AS to jointly develop and commercialize cancer treatment.

Under the terms of the agreement, AbbVie will pay Genmab $750 million in upfront payment and Genmab could receive up to $3.15 billion in additional development, regulatory and sales milestone payments.

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.